This study is looking into a new way to treat severe headaches that can happen after a subarachnoid hemorrhage (SAH), which is a type of bleeding around the brain. These headaches can be very painful and last a long time. The study will test if injecting two medications, Lidocaine hydrochloride and Methylprednisolone sodium succinate, directly into a specific artery in the head (the middle meningeal artery or MMA) can help reduce headache severity. You might be able to join if you are an adult (18 or older) with a confirmed SAH and are already having a procedure called DSA (digital subtraction angiography). The study will measure how much your headache pain changes over 12 weeks. The current status of this study is unclear, and it plans to enroll 25 participants.

Study design

This is a single-center study where all participants receive the treatment. It is an open-label study, meaning both you and the study team will know what treatment you are receiving. The study aims to enroll 25 participants.

What's involved

You would receive injections of Lidocaine hydrochloride and Methylprednisolone sodium succinate during a DSA procedure. Your headache severity will be measured at different times, including at discharge and at follow-up visits up to 12 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for headache severity from baseline up to 12 weeks after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.